Tests chemotherapy timing with radiation before surgery for rectal cancer
Compares chemotherapy given before surgery with standard treatment in rectal cancer patients.
Plain-language title generated from the registry record
Registry title: Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy for Rectal Cancer: A Randomized Controlled Trial
Key facts
- Where
- Larissa, GreeceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT05496491, who can take part
Where in Greece
- Department of Surgery, University Hospital of LarissaLarissa, GreeceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Larissa University Hospital
- Trial code
- NCT05496491
- Record updated
- 26 August 2026
- Original description
The purpose of this protocol is to compare neoadjuvant chemoradiation plus consolidation chemotherapy before surgical resection with the standard neoadjuvant chemoradiation followed by surgical resection and adjuvant chemotherapy in patients with rectal cancer.Read full original descriptionShow less
Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy for Rectal Cancer: A Randomized Controlled Trial
The purpose of this protocol is to compare neoadjuvant chemoradiation plus consolidation chemotherapy before surgical resection with the standard neoadjuvant chemoradiation followed by surgical resection and adjuvant chemotherapy in patients with rectal cancer.
Inclusion: Histologically confirmed rectal adenocarcinoma; cT3, cT4, threatened CRM / MRF, EMVI (+), ≥N1; Multidisciplinary tumor board decision for neoadjuvant treatment; Tumor distance from the anal verge <15 cm based on endoscopy or magnetic resonance imaging; Patient 18 to 80 years old; General health condition status WHO 0-1; Absence of co-morbidities that may affect treatment; Neutrophils >1,500 / mm3, platelets >100,000 / mm3, hemoglobin> 10 g / dL, normal creatinine, and creatinine clearance> 50 mL / min; Signed informed consent of the patient.
Exclusion: Contraindications for the administration of chemotherapy; Previous pelvic radiotherapy or chemotherapy; Non-resectable cancer; History of inflammatory bowel disorders; History of angina, acute myocardial infarction or heart failure; Active sepsis or systemic infection; Synchronous malignancy; Distant metastases; Untreated physical and mental disability; Pregnancy or breast-feeding; Lack of compliance with the protocol process; Non-granting of signed informed consent.